US · Healthcare · Biotechnology
EPS came in at -1.54 against a street estimate of -1.58 — a beat of 2.5%.
Analysts rate Disc Medicine Inc. a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $103.17.
| Fund | Stake |
|---|---|
| FMR Inc | 12.75% |
| BlackRock Inc | 6.43% |
| RA Capital Management, LLC | 6.38% |
| JPMorgan Chase & Co | 4.89% |
| T. Rowe Price Associates, Inc. | 4.88% |
| Wellington Management Company LLP | 4.54% |
| State Street Corp | 4.29% |
| Vestal Point Capital LP | 4.04% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 DISC MEDICINE, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Disc Medicine, Inc. (Nasdaq: IRON) • Report Date: September 9, 2026 • Location: Watert | 2026-09-10 |
| Quarterly report · Q2 2026 DISC MEDICINE, INC. – QUARTERLY SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $98.7 million in cash and cash equivalents as of June | 2026-07-30 |
| Results announced · Q3 2026 DISC MEDICINE, INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $717.7 million in cash, cash equivalents, and marketable s | 2026-07-30 |
| Material agreement · Q2 2026 DISC MEDICINE, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company drew down $30,000,000 from Tranche 1-B Advance on June 25, 2026 • Total available credi | 2026-06-30 |
| Shareholder vote results · Q2 2026 DISC MEDICINE, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting Date: June 18, 2026 • Total Votes Cast (Director Elections): Approximately 35.9 | 2026-06-24 |
| Quarterly report · Q1 2026 DISC MEDICINE, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and marketable securities combined: $730.2 million (March 31, 2026) vs. $791.2 mi | 2026-05-05 |
| Results announced · Q2 2026 DISC MEDICINE, INC. – Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $730.2 million in cash, cash equivalents, and marketable s | 2026-05-05 |
| Proxy statement · Q2 2026 DISC MEDICINE, INC. — 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Election of Three Class III Directors): Vote to elect Donald | 2026-04-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Disc Medicine Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.